Release of thromboxane B2 during adult respiratory distress syndrome and its inhibition by non steroidal anti-inflammatory substances in man. 1982

G Deby-Dupont, and L Radoux, and M Haas, and R Larbuisson, and F X Noël, and M Lamy

UI MeSH Term Description Entries
D012128 Respiratory Distress Syndrome A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA. ARDS, Human,Acute Respiratory Distress Syndrome,Adult Respiratory Distress Syndrome,Pediatric Respiratory Distress Syndrome,Respiratory Distress Syndrome, Acute,Respiratory Distress Syndrome, Adult,Respiratory Distress Syndrome, Pediatric,Shock Lung,Distress Syndrome, Respiratory,Distress Syndromes, Respiratory,Human ARDS,Lung, Shock,Respiratory Distress Syndromes,Syndrome, Respiratory Distress
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents
D013929 Thromboxane B2 A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin). B2, Thromboxane
D013931 Thromboxanes Physiologically active compounds found in many organs of the body. They are formed in vivo from the prostaglandin endoperoxides and cause platelet aggregation, contraction of arteries, and other biological effects. Thromboxanes are important mediators of the actions of polyunsaturated fatty acids transformed by cyclooxygenase. Thromboxane

Related Publications

G Deby-Dupont, and L Radoux, and M Haas, and R Larbuisson, and F X Noël, and M Lamy
August 1975, British journal of pharmacology,
G Deby-Dupont, and L Radoux, and M Haas, and R Larbuisson, and F X Noël, and M Lamy
January 1987, Intensive care medicine,
G Deby-Dupont, and L Radoux, and M Haas, and R Larbuisson, and F X Noël, and M Lamy
July 1986, Prostaglandins,
G Deby-Dupont, and L Radoux, and M Haas, and R Larbuisson, and F X Noël, and M Lamy
April 1989, La Revue du praticien,
G Deby-Dupont, and L Radoux, and M Haas, and R Larbuisson, and F X Noël, and M Lamy
January 1981, Journal of cardiovascular pharmacology,
G Deby-Dupont, and L Radoux, and M Haas, and R Larbuisson, and F X Noël, and M Lamy
January 1974, Polish journal of pharmacology and pharmacy,
G Deby-Dupont, and L Radoux, and M Haas, and R Larbuisson, and F X Noël, and M Lamy
June 1996, Alimentary pharmacology & therapeutics,
G Deby-Dupont, and L Radoux, and M Haas, and R Larbuisson, and F X Noël, and M Lamy
August 1987, Acta pathologica, microbiologica, et immunologica Scandinavica. Section C, Immunology,
G Deby-Dupont, and L Radoux, and M Haas, and R Larbuisson, and F X Noël, and M Lamy
August 1984, Pediatric research,
G Deby-Dupont, and L Radoux, and M Haas, and R Larbuisson, and F X Noël, and M Lamy
April 1983, Clinical science (London, England : 1979),
Copied contents to your clipboard!